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Summary
Objective: Sixty percent of synovial ﬂuids from patients with severe osteoarthritis (OA) contain calcium pyrophosphate dihydrate (CPPD) or
basic calcium phosphate (BCP) crystals. These bioactive crystals can be particularly difﬁcult to accurately identify in complex biologic
systems, such as in vitro models of crystal formation. We sought to determine if synchrotron Fourier Transform Infrared spectroscopy (sFTIR)
could be used to identify and characterize calcium-containing crystals in mineralization models.
Methods: CPPD and BCP crystals from porcine models of crystal formation were examined with an FTIR Microscope attached to a synchrotron
light source. As a comparison, crystals from human synovial ﬂuids were also examined. The sFTIR spectra generated were compared with
known spectra of multiple forms of BCP and CPPD crystals, as well as spectra generated by synthetic CPPD and BCP crystals and cartilage
proteoglycans, alone and in mixtures.
Results: sFTIR readily identiﬁed CPPD and BCP crystals in porcine models as well as in fresh synovial ﬂuids. Brushite was also present in
human and porcine samples, and whitlockite was seen in some porcine samples. Mixtures of minerals were commonly found in a single crystal
aggregate in both human and porcine samples. In spectra from many CPPD crystals, the peak at the 1134 cm1 found on the standard
spectrum for CPPD was diminished. Addition of spectra from cartilage proteoglycans to those of synthetic CPPD crystals dampened the
peak at this frequency region, much as this peak was diminished in biologically derived CPPD crystals.
Conclusion: sFTIR analysis allows for accurate identiﬁcation of CPPD and BCP crystals generated in vitro and will be a useful research tool to
study articular crystals.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis in
adults and currently affects over 20 million Americans.
Calcium-containing crystals, including calcium pyrophos-
phate dihydrate (CPPD) and hydroxyapatite-like basic
calcium phosphate (BCP) crystals are found in 60% of
synovial ﬂuids from unselected patients at the time of
knee replacement for OA1,2. BCP crystals are also associ-
ated with a severe destructive shoulder arthropathy known
as Milwaukee Shoulder Syndrome3. The presence of CPPD
and BCP crystals predict severe radiologic damage and
rapid progression of arthritis2,4.
In the laboratory, CPPD and BCP crystals have cata-
bolic effects on articular tissues. CPPD crystals can
induce a vigorous inﬂammatory response in the joint,
inducing the release of catabolic cytokines and proteases
from neutrophils and monocytes5. BCP crystals are also
inﬂammatory under certain conditions6. Independent of
inﬂammation, both CPPD and BCP crystals have direct*Address correspondence and reprint requests to: Dr Ann K.
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1395catabolic effects on chondrocytes and synovial cells.
They induce synovial cell mitogenesis7, and release
collagenase and other matrix-degrading proteases from
synoviocytes and chondrocytes8e10.
Much about the development of CPPD and BCP crystals in
OA is poorly understood11. The current paradigm involves an
alteration of the chondrocyte phenotype, induced by aging,
injury or OA. These chondrocytes assume characteristics
similar to those of the hypertrophic chondrocytes that produce
bone mineral during epiphyseal growth, such as overproduc-
tion of pyrophosphate (PPi), the anionic component of CPPD
crystals12. They also display altered production of key matrix
components involved in mineral formation13. PPi is generated
from exogenous adenosine triphosphate (ATP) by a variety of
ectoenzymes, and complexes with ambient calcium to form
CPPD crystals14. Inorganic phosphate can also be generated
by chondrocyte ectoenzymes. When phosphate rather than
PPi predominates, BCP mineral is generated. Mineral forma-
tion occurs in the pericellular matrix, and is facilitated by small
chondrocyte-derived extracellular organelles known as articu-
lar cartilage vesicles (ACVs)15.
Progress in understanding the role of calcium-containing
crystals in OA has been hampered by difﬁculties in their
identiﬁcation particularly in model systems16. In clinical
samples of joint ﬂuid and cartilage, CPPD crystals can be
identiﬁed by their characteristic rhomboid morphology and
positive birefringence under compensated polarizing light16.
1396 A. K. Rosenthal et al.: Characterization of articular calcium-containing crystalsAlizarin red S staining can be used to detect BCP crystals in
synovial ﬂuid, but is difﬁcult to interpret and also stains other
calcium-containing particulates17. Neither of these tech-
niques is sufﬁciently sensitive or accurate for research use.
Two well characterized models of calcium crystal forma-
tion include a model involving isolated ACVs15, and a chon-
drocyte tissue culture model18. In these models, crystals
tend to be very small, relatively sparse, and to be
surrounded by debris enriched in proteins, carbohydrates
and lipids, which interfere with many identiﬁcation tech-
niques. Thus, difﬁculties conclusively identifying the nature
and type of calcium crystals produced in these models have
limited their use.
Synchrotron Fourier Transform Infrared spectroscopy
(sFTIR) has been used to study mineralizing tissues,
such as bone, as well as cartilage19,20. It has proven use-
ful in the study of various factors inﬂuencing matrix miner-
alization in that it can be used quantitatively to estimate
amounts and quality of mineral formed21,22. Among the
many advantages of sFTIR are its high signal to noise ra-
tio (SNR), its ability to focus on very small areas in com-
plex specimens, and its usefulness with fresh wet
samples, requiring minimal preparation. In addition, the
ability to carefully map and characterize substances in
the areas in and around individual crystals has greatA
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Fig. 1. Representative sFTIR spectra from human synovial ﬂuids
demonstrating CPPD and BCP crystals. The crosshairs in the
visible images indicate the points at which the measurements
were obtained. The top sample spectrum was collected with
a 10 10-mm2 aperture and 64 scans, while the bottom sample
spectrum was collected with an 8 8-mm2 aperture and 64 scans.
For the latter crystal, the sample is clearly smaller than the
8 8-mm2 aperture, but is completely within the ﬁeld of view. The
infrared signatures produced by the synovial ﬂuid crystals clearly
match the standard spectra of BCP and CPPD crystals, respec-
tively. The additional peaks on the synovial ﬂuid crystal spectra
suggest the presence of biologic material mixed with the crystals.potential for yielding important information about crystal
formation and identifying modiﬁers of this process.
sFTIR can identify calcium-containing crystals generated
by in vitro models of crystal formation and illustrates their
remarkable similarity to crystals from human synovial ﬂuids.
sFTIR will be a useful research tool to further explore the
formation and role of calcium-containing crystals in OA.MethodsMATERIALSSynthetic CPPD crystals were generated in our laboratory using the
method of Brown et al.23. BCP crystals were a kind gift from Dr Neil Mandel
(National VA Crystal Identiﬁcation Center, Zablocki VA Medical Center,
Milwaukee, WI). Cartilage proteoglycans from human cartilage were
purchased from MD Biosciences (St Paul, MN). All other reagents were
from Sigma Chemical Co. (St. Louis, MO), unless otherwise speciﬁed.PORCINE CARTILAGEPorcine articular cartilage obtained from the knees of adult pigs (Johnson-
ville Foods, Inc., Watertown, WI) was used to generate chondrocytes for the
tissue culture model and ACVs for the ACV model.TISSUE CULTURE MODELA model of CPPD crystal formation in chondrocyte monolayers was
described by Ryan et al.18. In this system, high density primary cultures ofA
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Fig. 2. Representative sFTIR spectra from human synovial ﬂuid
demonstrating brushite alone and in combination with CPPD crys-
tals. Two crystals from human synovial ﬂuids were characterized
and compared to a brushite standard. The top spectrum represents
a crystal containing both CPPD and brushite components, while the
bottom spectrum appears to be pure brushite. The bottom spectrum
was measured with an 8 8-mm2 aperture, and the top one was
measured with a 10 10-mm2 aperture. Both measurements were
collected with 64 scans.
1397Osteoarthritis and Cartilage Vol. 16, No. 11normal articular chondrocytes generate CPPD crystals after 3e5 days of
incubation with 1-mM ATP. b-glycerophosphate is used as a control for
added phosphate. Cartilage pieces were enzymatically treated to remove
matrix as previously described and plated at 4 105 cells/cm2 for 2e3
days24 in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Mediatech, Hern-
don, VA) with 10% fetal calf serum. Media were replaced with serum-free
media for 24 h, and subsequently exposed to serum-free media containing
1-mM ATP, 1-mM b-glycerophosphate, or no additives for 3e5 days. Media
were then removed, and the cell layer was scraped from the plate and
subjected to sFTIR analysis.ACV MODELCartilage pieces were sequentially exposed to hyaluronidase, trypsin,
trypsin inhibitor and collagenase as previously described15. After an
overnight incubation with 0.05% collagenase, the mixture was ﬁltered,
centrifuged at 500 g for 15 min to remove cells, then at 37,000 g for
15 min to remove large cell fragments and organelles. The supernatant
was then centrifuged at 120,000 g for 60 min to pellet the ACV fraction.
Protein concentrations were determined by the Lowry assay25. The ACV-
containing pellet was re-suspended in DMEM to a protein concentration
of 12e15 mg/ml and mineralized with calcifying salt solution15 with or
without added ATP or b-glycerophosphate for 3e5 days. After incubation,
the crystal-containing pellets were centrifuged, and the supernatants were
removed.HUMAN SYNOVIAL FLUIDSSamples of human synovial ﬂuids from discarded synovial ﬂuid taken for
therapeutic or diagnostic purposes were obtained in accordance with the Insti-
tutional Review Board (IRB) at the Zablocki VA Medical Center. Five kneeA
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Fig. 3. Representative sFTIR spectra from porcine ACVs. ACVs
were incubated for 3e5 days with either 1-mM ATP or 1-mM b-glyc-
erophosphate. The crosshair identiﬁes the point at which the image
was collected for each sample. The top sample spectrum was col-
lected a 15 15-mm2 aperture as shown and 64 scans, while the bot-
tom sample spectrum was collected with a 12 12-mm2 aperture as
shown and 64 scans. The data for the mCPPD standard and the
ACV-generated CPPD-like crystal have been multiplied by two and
offset below 1500 cm1 to emphasize the comparison between the
spectra. The spectrum for the top sample is similar to BCP and
that the spectrum for the bottom sample is similar to mCPPD.ﬂuids containing CPPD crystals as determined by examination under polariz-
ing light microscopy were sealed to prevent drying, refrigerated for further use,
and used within 2 weeks of procurement. Two shoulder ﬂuids from patients
with clinical Milwaukee Shoulder syndrome in which we expected to ﬁnd
BCP crystals were similarly stored and used. Two knee ﬂuids without CPPD
crystals from patients with OA were also examined for crystals using sFTIR.FTIR STANDARDSStandard spectra of BCP, calcium phosphate (tribasic), and calcium phos-
phate (monobasic) crystals were obtained from the National Institute for
Standards and Technology (NIST) Chemistry Webbook. Standard spectra
of triclinic and monoclinic CPPD and orthorhombic calcium pyrophosphate
trihydrate (O-CPPT) were obtained from the VA Crystal Identiﬁcation Library
at the Zablocki VA Medical Center.
Spectra of synthetic crystals and cartilage proteoglycans were obtained
with a Bruker 66V FTIR spectrometer. Standard samples of crystals and/or
cartilage proteoglycans were compressed into Potassium Bromide (KBr)
pellets in a ratio of w19-mg KBr:1-mg Sample. The measurements were
taken in transmission with 8-cm1 resolution and a 6-mm aperture. The infra-
red spectra were obtained, via mathematical methods available with all
commercial infrared spectrometers, from the interferogram (i.e., the raw
data), using a fourpoint apodization function, which is a mathematical
construct to reduce spectral artifacts.sFTIRDrop-sized samples from the porcine models or human synovial ﬂuids
were applied to Kevley infrared (IR) reﬂective slides and examined with plain
and compensated polarized light microscopy to locate birefringent or dense
materials. These areas were photographed and marked so that the same
areas could be examined with sFTIR. The samples were measured withA
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Fig. 4. Representative sFTIR spectra from porcine chondrocyte
monolayers compared to human synovial ﬂuid. Chondrocyte mono-
layers were incubated with ATP for 72 h. A crystal from these
monolayers was compared with a CPPD crystal from human
synovial ﬂuid. The chondrocyte spectrum was collected with
a 12 12-mm2 aperture and 64 scans. The synovial ﬂuid spectrum
was collected with a 10 10-mm2 aperture and 64 scans. These
spectra are virtually identical.
1398 A. K. Rosenthal et al.: Characterization of articular calcium-containing crystalsa Thermo Fisher Continuum FTIR microscope coupled to an infrared beam-
line at the Synchrotron Radiation Center (SRC) in Stoughton, WI. Measure-
ments were taken in reﬂectance, acquiring reﬂection-absorbance results.
The detector was a mercuryecadmium telluride detector. Both individual
spot-measurements and spatially resolved maps of the samples were mea-
sured with apertures ranging from 8 8 to 15 15-mm2. The number of
scans was selected to optimize the SNR. Visible images were collected con-
currently. The infrared results were visually compared to reference spectra of
multiple forms of calcium-containing crystals and cartilage proteoglycans.ResultsSYNOVIAL FLUID CPPD AND BCP CRYSTALS AND OTHER
CRYSTALLINE FORMS ARE EASILY IDENTIFIED BY sFTIRFigure 1 displays the absorption standard spectra of BCP
and CPPD crystals, as well as visible images from synovial
ﬂuid samples. The crosshairs in the visible images indicate
the points at which the measurements were obtained. The
top sample spectrum was collected with a 10 10-mm2 ap-
erture and 64 scans, while the bottom sample spectrum
was collected with an 8 8-mm2 aperture and 64 scans.
The infrared signatures produced by the synovial ﬂuid crys-
tals clearly match the standard spectra of monoclinic BCP
and CPPD crystals, respectively.
Most CPPD crystals in synovial ﬂuids were monoclinic in
morphology. Hydroxyapatite, rather than octacalcium phos-
phate or tricalcium phosphate accounted for the majority of
the BCP crystals in synovial ﬂuid. Brushite (Ca (HPO4)
2H2O) was also identiﬁed in several synovial ﬂuids
(Fig. 2). It occurred alone and in combination with CPPD.
As illustrated in Fig. 1, amine peaks at 1598e1710 cm1,
and 1492e1598 cm1 were commonly seen in association
with crystals, supporting the presence of protein in or
around crystals. The carbohydrate peak characteristic of
proteoglycans is typically seen at 950e1150 cm1, 26, and
overlaps one of the signature CPPD peaks.Monolayer 
BOTH CPPD AND BCP CRYSTALS ARE PRESENT
IN MINERALIZED ACV SAMPLESA
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Standard Spectrum:
50% Proteoglycans, 30% M-CPPD,
20% BCPTwo images of spectra from crystals formed by ACVs are
shown in Fig. 3, along with the standard infrared spectra for
BCP and CPPD crystals. The crosshair identiﬁes the point
at which the image was collected for each sample. The
data for the CPPD standard and ACV-generated crystal
have been multiplied by two and offset below 1500 cm1
to emphasize the comparison between the spectra. One
can see that the spectrum for the top sample is similar to
BCP and that the spectrum for the bottom sample is similar
to monoclinic CPPD (mCPPD). Thus, not surprisingly,
ACVs are capable of generating both types of crystals.
While both forms of crystals were seen in many samples
regardless of the phosphate source, CPPD predominated
in samples incubated with ATP, and BCP crystals in sam-
ples incubated with b-glycerophosphate. Brushite and whit-
lockite were also noted in these samples (data not shown).
As in synovial ﬂuids, crystal-containing spectra in the ACV
preparations tended to include amine (protein) peaks.4000 3500 3000 2500 2000 1500 1000 500
Wavenumbers (cm-1)
Fig. 5. Representative sFTIR spectrum from a crystal generated byCPPD CRYSTALS IDENTICAL TO THOSE FOUND IN SYNOVIAL
FLUID ARE PRESENT IN CHONDROCYTE MONOLAYERS
INCUBATED WITH ATPchondrocyte monolayers and a mixture of BCP, CPPD and proteo-
glycans. The sFTIR spectrum from a crystal generated by chondro-
cyte monolayers was compared with an FTIR spectrum generated
by a combination of 50% cartilage proteoglycans, 30% mCPPD,
and 20% BCP.Figure 4 shows a comparison of spectra for CPPD
crystals produced in porcine chondrocyte monolayers and
CPPD crystals in human synovial ﬂuid. The bottom spec-
trum was collected from chondrocyte monolayers incubatedwith ATP. The top spectrum was collected from a sample of
human synovial ﬂuid. Note that the infrared absorbance is
very similar for the samples from the two models. However,
one of characteristic features of the CPPD spectrum, the
asymmetric stretch of the phosphorous-oxygen-phospho-
rous (POP) functional group represented by the peak
seen at 916e972 cm1, is slightly weaker on the crystal cre-
ated from the chondrocyte monolayers that those from
ACVs or synovial ﬂuids. Whether this is related to the orien-
tation of the crystal at the time at which it was measured is
not clear, but this possibility is currently being investigated.
Unlike ACVs, chondrocyte monolayers do not appear to
generate pure BCP crystals. Although an exhaustive search
for BCP crystals was not undertaken, BCP mineral only
appeared in conjunction with CPPD mineral.CRYSTALS IN PORCINE MODELS AND SYNOVIAL FLUIDS
CONTAIN MANY REGIONS THAT ARE MIXTURES
OF MINERAL AS WELL AS PROTEOGLYCANSWe also noted that many individual crystals contained
regions that did not exactly match either pure CPPD or
pure BCP crystals, and investigated the possibility that
these regions contained both CPPD and BCP minerals.
Figure 5 shows a typical spectrum from a crystal gener-
ated by chondrocyte monolayers treated with ATP. It
was almost an identical match to a combination of 30%
CPPD and 20% BCP (data not shown). However, we fre-
quently noted that the peak at 1134 cm1 of CPPD in both
human and porcine samples was often blunted compared
1399Osteoarthritis and Cartilage Vol. 16, No. 11to the spectra generated by synthetic mCPPD crystals,
and wondered about the contribution of carbohydrate
moieties to this blunting. The carbohydrate peak is located
at 950e1150 cm1 and might logically alter the CPPD
peak at 1134 cm1. Figure 5 shows a spectrum from this
crystal compared with a standard spectrum generated
from a combination of 50% proteoglycans, 30% mCPPD,
and 20% BCP. The addition of the proteoglycan spectrum
resulted in blunting of the CPPD peak at 1134 cm1 sim-
ilar to that seen in the biologic samples. These ﬁndings
support the presence of proteoglycans on or near CPPD
crystals and explain the altered morphology of this signa-
ture peak in many biologic samples.THIS TECHNOLOGY ALLOWS FOR CAREFUL
MAPPING OF AN INDIVIDUAL CRYSTALBCP and CPPD crystals, as well as mixtures of the two,
were found within close proximity to each other. Figure 6 is
a map from a crystal generated by ACVs, while Fig. 7 is4000 3000 200
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Fig. 6. sFTIR map of a typical crystal generated by ACVs. The data, 110 p
and 64 scans per pixel. Panel B shows a visible image of the crystal with
(panels A and C) are shown that are dominated by the absorbance of fun
spectral range for BCP was 985e895 cm1 and for CPPD was 1015e115
intensity and can be indicative of the presence of the crystal functional g
tional group and absence of the functional group. The remaining panels (
pixels identiﬁed in the infrared images and compare them to combinatio
additional peaks arising from admixture of biologic material. The infrared
and brushite minerals in a sia map from a synovial ﬂuid crystal. Oversampling was
used, collecting infrared spectra in 8-mm steps to achieve
higher quality resolution on the maps. A total of 110
(10 11) pixels are displayed on the maps.
The ACV-generated crystal was mapped in regards to
CPPD and BCP. Panel B represents the visible image,
while panels A and C are infrared images of the visible
image. Red areas on the infrared images indicate areas
with high absorption and are indicative of marked similar-
ity to the functional group, whereas blue areas indicate
low amounts of absorption by the functional group in
question, and are areas that are very different from the
functional group. Panel A is an infrared image where
red color indicates similarity to BCP mineral and is inte-
grated over 950e895 cm1. Similarly, panel C is an infra-
red map where red indicates strong similarity to CPPD
mineral and is integrated over 1015e1150 cm1. Points
1e5 indicate speciﬁc spectra at these points on the
map, and most match best with a mixture of CPPD,
BCP and brushite.0 1000
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ns of CPPD, BCP and brushite. All of the sample spectra contain
images and spectra suggest superimposed areas of CPPD, BCP
ngle crystal aggregate.
1400 A. K. Rosenthal et al.: Characterization of articular calcium-containing crystalsFor the synovial ﬂuid crystal (Fig. 7), proﬁles indicating
the absorbance of a particular functional group were
calculated on the map for different functional groups spe-
ciﬁc to BCP and CPPD, respectively. The functional group
used to identify BCP occupied the region from 985 to
1155 cm1, and this is shown in panel A, while the func-
tional group speciﬁc to CPPD occupied the region from
1125 to 1201 cm1 is shown in panel C. Panel B represents
the visible image. The map suggests superimposed or
adjacent areas of CPPD and BCP minerals in a single crys-
tal aggregate.Discussion
We show here that sFTIR can be used to conclusively
identify CPPD and BCP crystals in low frequency, high
background samples such as biologic models. Clearly,
while this technology will remain a research tool, it has
important implications for our understanding of these crys-
tals in disease. sFTIR has many advantages over traditional
methods of crystal identiﬁcation. In contrast to X-ray dif-
fraction and traditional FTIR, it requires minimal sample
preparation, limiting concerns about creating artifactual
crystals or further reducing already sparse crystals. It canPoin
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ple, and its high SNR and is ideally suited to characterize
these tiny crystals in a sea of other components. Further-
more, the polarized quality of the synchrotron beam may
yield important information about crystal polarity that may
reveal clues as to how these pathogenic crystals grow.
This technology is not without limitations, however,
measurements of samples containing large quantities of
relatively pure crystal can be easily performed in a labora-
tory with a similar infrared microscope. Measurements of
less pure samples with small and sparse crystals require
access to a synchrotron source. There are only four
national synchrotron user facilities equipped with the proper
facilities to perform these experiments; so access to this
technology is certainly limited and requires considerable
expertise and potential expense.
These studies reinforce the validity of these in vitro
models of crystal formation and provide important informa-
tion about these models. While conventional FTIR studies
demonstrated the presence of CPPD and BCP crystals in
ACVs, until now, CPPD crystals in the monolayer model
had only been putatively identiﬁed18. The absence of pure
BCP crystals in the monolayer model also has important
implications about the process of crystal formation. This cor-
roborates previous studies showing that adding phosphate toPoint 6
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1401Osteoarthritis and Cartilage Vol. 16, No. 11chondrocyte monolayers produces no increase in calciﬁca-
tion, while adding ATP strongly stimulates mineralization13.
In contrast, ACVs mineralize with the addition of phosphate
or ATP. While monolayers and ACVs share similar mineral-
ization regulating enzymes, it is likely that the extracellular
matrix surrounding chondrocytes in monolayer culture per-
mits CPPD crystal formation in the presence of ATP, but
prevents BCP mineral from forming.
We were quite surprised at the numbers of crystal aggre-
gates that contained both CPPD and BCP minerals.
Although CPPD and BCP crystals commonly co-exist clini-
cally27, their relationship to one another etiologically and in
cartilage remains controversial. For example, in intact
human cartilage, Pritzker et al. found only two of 23 sam-
ples of cartilage with CPPD crystal deposits also contained
BCP crystals28. They based their ﬁndings on morphologic
differences between the crystal types as well as electron
diffraction results obtainable only with sufﬁcient hydroxyap-
atite loads. Synovial ﬂuid studies, however, suggest a much
more common coexistence, and Gordon et al. noted
frequent calciﬁcations in cartilage affected by OA, but
were unable to further characterize these deposits29. While
a paucity of pure BCP crystals was certainly reﬂected in our
monolayer model, many CPPD crystals from both human
and porcine samples contained some BCP mineral. PPi
can inhibit BCP crystal growth30, but whether BCP crystals
can coat the surface and limit the size of CPPD crystals
remains unclear.
Crystals were always found in association with protein,
and in the case of CPPD crystals, proteoglycans were of-
ten present. The interference of the carbohydrate peak
with one of the characteristic spectral peaks of CPPD, ex-
plains why the peaks of biologic crystals may not exactly
match reference FTIR spectra. It also suggests that pro-
teoglycans, which are traditionally considered inhibitors
of mineralization, are found in close contact with crystals.
It is difﬁcult to discern from our data whether crystals are
coated with protein or proteoglycan or these substances
are mixed within the crystal itself. Further work to deter-
mine the spatial relationships of crystal components by
measuring spectra in transmission rather than reﬂectance,
is ongoing in our laboratory and may yield this important
information.
Previous studies have used FTIR with or without
a synchrotron light source to investigate cartilage in OA.
For example, Bi et al. recently used a similar technique
without a synchrotron-generated beam to non-invasively
characterize changes in articular cartilage in a model of
rabbit OA26. They correlated collagen and proteoglycan
content with the area under certain peaks and could also
examine collagen degradation using a peak at 1338 cm1.
Other studies have used sFTIR to measure mineral quantity
in bone as well as to determine the matrix to mineral ratio,
a key measure of bone ‘‘quality’’. It is hoped that the
application of this technique to crystals in situ in articular
cartilage may yield similar quantitative information as well
as important information about changes in the extracellular
matrix that may regulate mineral formation.
We were also able to document the presence of brushite
in both human and porcine samples. Brushite is a hydrated
form of calcium phosphate that has an inﬂammatory poten-
tial similar to that of hydroxyapatite31. It has also been pro-
posed to be one of the earliest forms of calcium phosphate
crystal generated during bone mineralization32 and may
appear similar radiographically to chondrocalcinosis33.
The role of brushite in arthritis and the conditions favoring
its formation certainly warrant further investigation.Whitlockite was seen in the porcine samples but not in
synovial ﬂuid samples, and the signiﬁcance of this ﬁnding
is uncertain. Whitlockite and other magnesium-containing
calcium phosphate crystals are well documented in normal
and osteoarthritic articular cartilage34, and recently have
been seen in human intervertebral discs alone and in asso-
ciation with CPPD crystals35. They are less inﬂammatory
then non-magnesium-containing calcium crystals36. These
interesting crystals are also found in cases of metastatic
pulmonary calciﬁcation complicating end stage renal dis-
ease37, as well as in other forms of pathologic calciﬁcation38.
In summary, we show here that sFTIR can be used to
identify small and sparse calcium-containing crystals in
models of crystal formation as well as in human synovial
ﬂuids. Brushite and whitlockite were identiﬁed in these
samples. These ﬁndings reinforce the frequent occurrence
of both CPPD and BCP crystals in a single crystal aggre-
gate. They emphasize the common association of crystals
with proteins and proteoglycan and validate the monolayer
model of CPPD crystal formation. Further application of this
exciting technology should give us additional information
about these important crystals.Conﬂict of interest
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